查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1990069

动物模型市场：依动物种类、模型类型、应用和最终用户划分－2026-2032年全球市场预测

Animal Model Market by Animal Type, Model Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物模型市场价值将达到 34.2 亿美元，到 2026 年将成长到 36.8 亿美元，到 2032 年将达到 59.8 亿美元，复合年增长率为 8.27%。

主要市场统计数据
基准年 2025 34.2亿美元
预计年份：2026年 36.8亿美元
预测年份 2032 59.8亿美元
复合年增长率 (%) 8.27%

全面介绍科学进步、伦理要求和监管期望如何交织并重新定义临床前动物模型策略。

现代动物模型环境正处于快速科学创新、严格的伦理要求和不断发展的法律规范三者交汇的十字路口。临床前研究人员和机构领导者必须应对日益复杂的环境，基因编辑技术的进步、繁殖管理和模型表征的改进以及复杂的重复性标准都会影响决策。随着研究机构、製药公司和服务供应商不断调整，明确模型选择、营运弹性和合规性对于维持转化研究流程至关重要。

基因编辑、以福利为中心的管治和数位整合如何改变模型开发、检验方法和合作研究框架？

生物医学研究领域正在发生一场突破性的变革，重塑着动物模型的发展、检验和应用方式。精准基因编辑技术的进步，特别是基于CRISPR的技术，正在加速建立高度特异性的基因修饰模型，这些模型能够更真实地模拟人类疾病的生物学过程，从而改变模型选择和实验设计的标准。同时，表型表征和体内成像技术的进步正在提升纵向研究能力，并减少获得可靠终点所需的动物数量，进而影响资源分配和研究进度安排。

2025 年美国贸易措施变化对临床前供应链、采购韧性和跨境合作准备的影响。

美国预计2025年推出的政策干预措施和关税调整，将为临床前供应链和跨国合作带来新的考量。影响特殊生物材料、客製化试剂和设备进出口的贸易措施，可能会影响采购前置作业时间和供应商选择。因此，依赖国际供应商提供基因改造菌株、种畜或特殊耗材的机构，可能需要调整筹资策略，以减轻进口合规审查加强和潜在成本重新分配对其营运的影响。

实用的细分情报揭示了物种选择、模型建构、应用领域和最终用户概况如何产生不同的营运和科学优先事项。

细分洞察揭示了不同的动物物种、模型配置、应用领域和最终用户如何塑造临床前生态系统中不同的需求和策略重点。在物种层面，可区分非囓齿类动物和囓齿类动物。非囓齿类动物包括犬、非人灵长类动物和兔等物种，而囓齿类动物则包括仓鼠、豚鼠、小鼠和大鼠。这种生物多样性导致了法律规范、饲养要求和转化应用的差异。因此，物种选择决策越来越依赖生理有效性和操作性考量（例如繁殖週期、饲养空间和动物福利通讯协定）之间的平衡。

区域分析揭示了美洲、欧洲、中东和非洲以及亚太地区如何影响采购、合规和合作研究策略。

区域趋势影响着各组织在关键区域内动物模型采购、监管合规和合作研究策略的做法。美洲仍然是治疗方法创新和合约研究的中心，学术机构和商业赞助商之间紧密的网络推动着对成熟模型和专业服务的需求。这种能力的集中支撑着强大的转化研究项目，同时也加剧了对人才、基础设施和实验室空间的竞争，从而促进了战略伙伴关係和资源共用模式的建立，以优化研究效率。

为那些透过在服务交付中实现专业化、资料整合和监管合规来推动竞争差异化的公司提供策略行动和伙伴关係模式。

动物模型生态系统中的关键企业行动体现了围绕专业化、垂直整合和协作服务交付的策略重点。主要企业正投资于高保真基因工程技术和强大的育种项目，以提供差异化的模型产品组合；与此同时，许多服务公司正在拓展其分析和生物资讯层面，以提供动物生产以外的增值服务。这种将技术服务与更深入的数据解读相结合的趋势旨在弥合转化医学鸿沟，并为申办方提供来自临床前计画的更具可操作性的见解。

为研究领导者提供切实可行、优先排序和具有策略意义的建议，以加快转化成果的实现，同时提高模型准确性、加强供应链并增强福利合规性。

产业领导者应积极整合科学研究投入、供应链韧性和强化管治，以最大限度地掌握现有机会并降低新兴风险。首先，整合先进的基因修饰建模能力（特别是基于 CRISPR 的平台和全面的表型分析工作流程）能够提高目标有效性，并降低下游转化研究的不确定性。同时，各组织应制定模型表征标准，并建立跨职能审查流程，以确保研究结果的可重复性和科学证据的有效性。

结合专家访谈、系统性文献整合和迭代检验的稳健的多源调查方法，确保了有效且可操作的见解。

本分析的调查方法采用多层次策略，将初步质性研究结果与结构化的二次检验结合。初步研究内容包括咨询各领域专家，涵盖临床前研究、兽医学和监管事务等，以捕捉细微的营运实际情况和新兴科学趋势。除访谈外，还对同行评审文献、技术指导文件和认证标准进行了系统性回顾，以阐明技术进步和动物福利实践的背景。

一项决定性的整合凸显了整合科学精确性、道德管治和供应链韧性的必要性，以维持转化研究的成功。

总之，动物模型领域正进入一个深化专业知识、加强伦理课责、调整营运模式的阶段。科学进步，特别是基因编辑和表型表征方面的进步，正在提高模型转化应用的准确性，同时监管机构和相关人员也在提高动物福利和可重复性方面的标准。这些并行发展要求各机构谨慎选择模型，提高供应链的灵活性，并投资于数据和管治基础设施，以支持可靠的转化研究结果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物模型市场：依动物类型划分

  • 不囓齿类动物
    • 狗
    • 非人灵长类动物
    • 兔子
  • 囓齿动物
    • 仓鼠和天竺鼠
    • 老鼠
    • 鼠

第九章：依模型类型分類的动物模型市场

  • 疾病模型
  • 基因改造模型
    • CRISPR模型
    • 敲入式模型
    • 淘汰赛模特儿
    • 基因改造模型
  • 药理学模型
  • 手术模型

第十章：动物模型市场：依应用领域划分

  • ADME 和 PK 测试
  • 疾病调查
  • 药物发现与开发
  • 毒性评估

第十一章：动物模型市场：依最终使用者划分

  • 学术和研究机构
  • 合约研究机构
  • 医院和诊断检测机构
  • 製药和生物技术公司

第十二章 动物模型市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：动物模型市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 动物模型市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国动物模型市场

第十六章：中国动物模型市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aurora BioSolutions
  • Biocytogen
  • Charles River Laboratories International Inc.
  • Crown Bioscience Inc.
  • Cyagen Biosciences Inc.
  • Envigo RMS LLC
  • Genoway
  • Hera BioLabs
  • ingenious targeting laboratory
  • Inotiv
  • Janvier Labs
  • Mirimus Inc.
  • Ozgene Pty Ltd
  • PhoenixBio Co. Ltd.
  • PolyGene AG
  • Taconic Biosciences Inc.
  • The Jackson Laboratory
  • Transgenic Inc.
Product Code: MRR-5D693B46BD18

The Animal Model Market was valued at USD 3.42 billion in 2025 and is projected to grow to USD 3.68 billion in 2026, with a CAGR of 8.27%, reaching USD 5.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.42 billion
Estimated Year [2026] USD 3.68 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 8.27%

A comprehensive introduction outlining how scientific progress, ethical imperatives, and regulatory expectations converge to redefine preclinical animal model strategies

The contemporary animal model landscape sits at the intersection of rapid scientific innovation, stringent ethical expectations, and evolving regulatory oversight. Preclinical investigators and organizational leaders must navigate an increasingly complex environment where advances in gene editing, improvements in husbandry and model characterization, and heightened reproducibility standards collectively influence decision-making. As research institutions, pharmaceutical developers, and service providers adapt, the demand for clarity around model selection, operational resilience, and compliance has become central to sustaining translational pipelines.

Across this environment, stakeholders are placing greater emphasis on validated disease models and genetically engineered systems to increase translational relevance while simultaneously responding to external pressures to refine animal use and enhance welfare. This dynamic requires a nuanced understanding of model capabilities and limitations, as well as strategies for integrating alternative technologies where appropriate. Consequently, the ability to align scientific objectives with operational structures, vendor ecosystems, and regulatory expectations is now a critical determinant of project success and ethical stewardship.

How gene editing, welfare-driven governance, and digital integration are jointly transforming model development, validation practices, and collaborative research frameworks

Significant transformative shifts are reshaping how animal models are developed, validated, and deployed across biomedical research. Advances in precision gene editing, particularly CRISPR-based approaches, are accelerating the creation of highly specific genetically engineered models that better recapitulate human disease biology, thereby changing the calculus for model selection and experimental design. At the same time, improvements in phenotype characterization and in vivo imaging are enhancing longitudinal study capabilities and reducing the number of animals required for robust endpoints, which in turn affects resource allocation and study timelines.

Concurrently, ethical and regulatory landscapes are exerting stronger influence over experimental practice. Institutions and sponsors are strengthening governance frameworks to align with international 3Rs principles, resulting in more rigorous welfare monitoring and justification for animal use. In response, service providers and internal teams are increasingly investing in welfare-positive housing, enrichment programs, and staff training to meet both ethical expectations and scientific quality goals. In parallel, digital transformation and data integration-encompassing laboratory information management systems, standardized metadata practices, and machine learning-enabled analytics-are improving reproducibility and enabling more rapid cross-study comparisons. These combined shifts are driving a migration toward collaborative networks of specialized providers, centralized model repositories, and multidisciplinary teams that can deliver higher-confidence translational outputs.

Implications of evolving US trade measures for preclinical supply chains, procurement resilience, and cross-border collaboration preparedness in 2025

Policy interventions and tariff adjustments in the United States projected for 2025 are introducing new considerations for preclinical supply chains and cross-border collaborations. Trade measures that affect the import and export of specialized biological materials, custom reagents, and equipment can influence procurement lead times and vendor selection decisions. As a result, organizations that rely on international suppliers for genetically engineered lines, breeding stock, or specialized consumables may need to reassess sourcing strategies to mitigate the operational impact of elevated import compliance scrutiny and potential cost reallocation.

In practical terms, these trade dynamics are prompting greater attention to supplier diversification, onshoring of critical production capabilities, and regionalization of supply chains where feasible. Organizations are emphasizing contractual protections, enhanced inventory planning, and multi-supplier qualification to ensure continuity of studies and reduce exposure to policy-driven disruptions. Moreover, the tariffs dialogue is catalyzing conversations between industry stakeholders and regulatory authorities about harmonizing standards for material transfer, quarantine, and documentation to minimize administrative friction. Ultimately, the implication for research programs is a need to integrate trade policy risk into project timelines and procurement governance so that scientific objectives remain resilient in the face of shifting cross-border rules.

Actionable segmentation intelligence revealing how species selection, model construction, application focus, and end-user profiles create differentiated operational and scientific priorities

Segmentation insights reveal how distinct animal types, model constructs, application areas, and end users shape heterogeneous demands and strategic priorities across the preclinical ecosystem. The animal type dimension differentiates Nonrodents and Rodents, where Nonrodents encompass species such as Dogs, Nonhuman Primates, and Rabbits, and Rodents include Hamsters & Guinea Pigs, Mice, and Rats; this biological diversity drives variation in regulatory oversight, housing requirements, and translational applicability. Therefore, decisions about species selection are increasingly informed by the balance between physiological relevance and operational considerations such as breeding cycles, housing footprint, and welfare protocols.

Model type granularity further layers complexity: Disease Models, Genetically Engineered Models, Pharmacological Models, and Surgical Models each serve distinct experimental purposes. Within genetically engineered approaches, subdivisions such as CRISPR Models, Knock-In Models, Knockout Models, and Transgenic Models differ in their technical construction and applicability for target validation, mechanistic studies, and therapeutic testing. These differences influence not only experimental design but also validation pathways and reproducibility expectations, leading organizations to develop tailored standard operating procedures and characterization pipelines for each model class.

Applications span ADME & PK Studies, Disease Research, Drug Discovery & Development, and Toxicology Assessment, and each application imposes unique fidelity requirements, endpoint selection, and data provenance needs. For instance, ADME and pharmacokinetic investigations prioritize controlled physiology and precise sampling, whereas disease research may require complex phenotyping and longitudinal outcome measures. As a result, operational investments in assay platforms, imaging modalities, and bioanalytical capacity are frequently aligned to the dominant application portfolio of an organization.

End users range from Academic & Research Institutes to Contract Research Organizations, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies, each bringing different procurement behaviors, regulatory responsibilities, and timelines. Academic labs often prioritize exploratory flexibility and open science practices, while contract research organizations focus on scalable, validated workflows that meet sponsor requirements. Clinical laboratories and health systems integrate preclinical insights into translational pathways and diagnostic development, and industry partners require robust model justification to support regulatory submissions. Recognizing these segmentation-driven differences enables stakeholders to align model selection, vendor partnerships, and governance frameworks with the specific needs of their primary end-user constituencies.

Regional analysis highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each influence sourcing, compliance, and collaborative research strategies

Regional dynamics are shaping how organizations approach animal model sourcing, regulatory compliance, and collaboration strategies across key geographies. The Americas continue to be a hub for therapeutic innovation and contract research activity, with dense networks of academic institutions and commercial sponsors that drive demand for characterized models and specialized services. This concentration of capability supports robust translational programs, yet it also elevates competition for talent, infrastructure, and laboratory space, encouraging strategic alliances and shared-resource models to optimize throughput.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and ethical norms that influence model development and cross-border exchanges. Many jurisdictions in this region emphasize stringent welfare standards and harmonized oversight, which in turn shape vendor certification practices and study design expectations. Additionally, collaborative pan-regional consortia and public-private partnerships play a notable role in pooling resources for large-scale preclinical initiatives and in advancing standardized model validation criteria.

Asia-Pacific has emerged as a dynamic region for both service provision and model innovation, with rapid investment in gene editing capacity, breeding infrastructure, and contract research capabilities. Diverse regulatory approaches across countries create opportunities for regional specialization, while increasing local scientific expertise is fostering indigenous model development and translational research programs. Together, these regional patterns highlight the importance of tailoring sourcing strategies, compliance roadmaps, and partnership approaches to the specific risks and advantages present within each geography.

Strategic company behaviors and partnership models that drive competitive differentiation through specialization, data integration, and regulatory-aligned service offerings

Key company behaviors in the animal model ecosystem reflect strategic prioritization around specialization, vertical integration, and collaborative service delivery. Leading providers are investing in high-fidelity genetically engineered capabilities and robust breeding programs to offer differentiated model portfolios, while many service firms are expanding their analytics and bioinformatics layers to add value beyond animal production. This trend toward bundling technical services with deeper data interpretation aims to reduce translational gaps and to provide sponsors with more actionable insights from preclinical programs.

Another notable direction is the consolidation of capabilities through partnerships and alliances, enabling organizations to combine operational strengths-such as vivarium management, regenerative medicine expertise, or in vivo imaging-into comprehensive service offerings. At the same time, some providers are pursuing modular, outsourced arrangements that allow sponsors to access specific competencies without committing to full-scale integration. Across these strategies, investment in regulatory intelligence, quality management systems, and welfare accreditation is common, as customers increasingly demand demonstrable standards and traceability across the supply chain. These company-level choices influence competitive positioning, client retention, and the evolution of service-level expectations across the sector.

Practical and prioritized strategic recommendations for research leaders to enhance model fidelity, fortify supply chains, and elevate welfare compliance while accelerating translational outcomes

Industry leaders should adopt a proactive mix of scientific investment, supply chain resilience, and governance enhancements to capitalize on current opportunities and mitigate emerging risks. First, embedding advanced genetically engineered model capabilities-especially CRISPR-enabled platforms and comprehensive phenotyping workflows-will improve target validation and reduce downstream translational uncertainty. Complementing this, organizations should formalize model characterization standards and establish cross-functional review processes that ensure reproducibility and defendable scientific rationale.

Second, supply chain strategies must evolve to reduce exposure to trade policy shifts and supply interruptions. This involves diversifying vendor relationships, qualifying regional suppliers, and developing contingency inventories for mission-critical materials. In addition, investing in localized breeding capacity or regional partnerships can shorten lead times and provide operational buffers during periods of commerce volatility. Third, companies should elevate welfare and compliance governance by integrating enhanced monitoring technologies, independent audits, and staff competency programs that align with evolving ethical expectations and regulatory scrutiny.

Finally, leaders should leverage data science and digital platforms to achieve higher experimental efficiency. Standardizing metadata capture, adopting interoperable laboratory systems, and deploying machine learning for endpoint prediction will increase reproducibility and support faster decision cycles. Combined, these actions enhance scientific credibility, operational stability, and stakeholder trust, positioning organizations to sustain translational momentum while remaining responsive to policy and ethical imperatives.

Robust multi-source research methodology combining expert consultations, systematic literature synthesis, and iterative validation to ensure defensible and actionable insights

The research methodology underpinning this analysis leverages a layered approach that synthesizes primary qualitative insights with structured secondary validation. Primary inputs include consultations with subject-matter experts across preclinical research, veterinary sciences, and regulatory affairs to capture nuanced operational realities and emerging scientific trends. These interviews were supplemented by a systematic review of peer-reviewed literature, technical guidance documents, and recognized standards to contextualize technological advances and welfare practices.

Data triangulation ensured robustness by cross-referencing expert perspectives with publicly available technical reports and documented policy changes. Wherever applicable, methodological transparency was maintained through clear documentation of inclusion criteria, definitions for model classes, and the provenance of technical assertions. Ethical considerations guided the process throughout, with respect for data privacy and professional confidentiality in all expert engagements. This multi-source, iterative approach supports a defensible interpretation of sector dynamics and yields insights tailored to decision-makers requiring both operational guidance and scientific credibility.

A conclusive synthesis emphasizing the need to integrate scientific precision, ethical governance, and supply chain resilience to sustain translational success

In conclusion, the animal model landscape is entering a period of refined specialization, heightened ethical accountability, and operational recalibration. Scientific advances-especially in gene editing and phenotype characterization-are improving the translational precision of models, while at the same time regulators and stakeholders are raising the bar for welfare and reproducibility. These concurrent forces require organizations to be deliberate in model selection, to strengthen supply chain agility, and to invest in data and governance infrastructures that support reliable translational outcomes.

Looking forward, success will depend on the ability to integrate technological capabilities with responsible stewardship and pragmatic operational planning. Organizations that proactively align their scientific agendas with resilient procurement practices and transparent welfare governance will be better positioned to deliver high-quality preclinical evidence and to respond to policy or market shifts with agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Market, by Animal Type

  • 8.1. Nonrodents
    • 8.1.1. Dogs
    • 8.1.2. Nonhuman Primates
    • 8.1.3. Rabbits
  • 8.2. Rodents
    • 8.2.1. Hamsters & Guinea Pigs
    • 8.2.2. Mice
    • 8.2.3. Rats

9. Animal Model Market, by Model Type

  • 9.1. Disease Models
  • 9.2. Genetically Engineered Models
    • 9.2.1. CRISPR Models
    • 9.2.2. Knock-In Models
    • 9.2.3. Knockout Models
    • 9.2.4. Transgenic Models
  • 9.3. Pharmacological Models
  • 9.4. Surgical Models

10. Animal Model Market, by Application

  • 10.1. ADME & PK Studies
  • 10.2. Disease Research
  • 10.3. Drug Discovery & Development
  • 10.4. Toxicology Assessment

11. Animal Model Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Animal Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Model Market

16. China Animal Model Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aurora BioSolutions
  • 17.6. Biocytogen
  • 17.7. Charles River Laboratories International Inc.
  • 17.8. Crown Bioscience Inc.
  • 17.9. Cyagen Biosciences Inc.
  • 17.10. Envigo RMS LLC
  • 17.11. Genoway
  • 17.12. Hera BioLabs
  • 17.13. ingenious targeting laboratory
  • 17.14. Inotiv
  • 17.15. Janvier Labs
  • 17.16. Mirimus Inc.
  • 17.17. Ozgene Pty Ltd
  • 17.18. PhoenixBio Co. Ltd.
  • 17.19. PolyGene AG
  • 17.20. Taconic Biosciences Inc.
  • 17.21. The Jackson Laboratory
  • 17.22. Transgenic Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)